FDA
-
-
-
-
-
-
-
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
-
-
-
-
-
-
-
Goldman Sachs: 'we view DNLI as attractive given the aforementioned dynamics'
-
-
-
-
-
-
-
Denali Therapeutics (DNLI) Confident of 2026 Approval for tivi/DNL310 - Stifel
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
-
-
-
-
-
-
-
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
-
-
-
-
-
-
-
Morgan Stanley Starts Denali Therapeutics Inc. (DNLI) at Overweight
-
323,571 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

